Core Viewpoint - 康沣生物-B (06922.HK) reported significant revenue growth and reduced losses for the six months ending June 30, 2025, driven by increased sales of respiratory intervention products following regulatory approval [1] Financial Performance - Revenue increased to RMB 51.1 million, representing a year-on-year growth of 162.4% [1] - Losses decreased from RMB 56.0 million for the six months ending June 30, 2024, to RMB 27.2 million for the same period in 2025, a reduction of RMB 28.8 million or 51.4% [1] Product Development - The revenue growth was primarily attributed to the sales increase of the malignant stenosis cryoablation system and cryoadhesion treatment system, which received approval from the National Medical Products Administration in March 2025 [1] - Additionally, sales of other respiratory intervention products distributed by 波科国际医疗贸易 (Shanghai) Co., Ltd. also contributed to the revenue increase during the reporting period [1]
康沣生物-B(06922.HK)中期收入5110万元 同比增长162.4%